{"id":75772,"date":"2026-08-21T12:19:36","date_gmt":"2026-08-21T04:19:36","guid":{"rendered":"https:\/\/flcube.com\/?p=75772"},"modified":"2026-08-21T12:19:37","modified_gmt":"2026-08-21T04:19:37","slug":"longbio-pharmas-lp-003-bla-accepted-by-nmpa-for-seasonal-allergic-rhinitis-advancing-novel-anti-ige-antibody-toward-china-approval","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75772","title":{"rendered":"LongBio Pharma&#8217;s LP\u2011003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti\u2011IgE Antibody Toward China Approval"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>LongBio Pharma (Suzhou) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1779:HKG\">HKG: 1779<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has accepted its <strong>Biologics License Application (BLA)<\/strong> for <strong>LP\u2011003<\/strong>, an anti\u2011IgE antibody candidate, for the treatment of <strong>seasonal allergic rhinitis<\/strong> \u2014 marking a key regulatory step toward commercial approval.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>Biologics License Application (BLA) \u2014 accepted<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>LP\u2011003 (anti\u2011IgE antibody)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Seasonal allergic rhinitis<\/td><\/tr><tr><td><strong>Sponsor<\/strong><\/td><td>LongBio Pharma (Suzhou) Co., Ltd. (HKG: 1779)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>21 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>LP\u2011003<\/strong>, an anti\u2011IgE antibody featuring a <strong>novel sequence design<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Blocks free IgE in both blood and tissues, thereby inhibiting IgE\u2011mediated allergic reactions at their source<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> The novel sequence design is positioned to offer potential advantages in binding, efficacy, or tolerability relative to incumbent anti\u2011IgE therapies<\/li>\n\n\n\n<li><strong>Therapeutic Logic:<\/strong> By neutralizing free IgE, <strong>LP\u2011003<\/strong> targets the central driver of a broad range of allergic conditions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-pipeline-breadth-multiple-indications-in-motion\" class=\"wp-block-heading\">Pipeline Breadth \u2013 Multiple Indications in Motion<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>LP\u2011003<\/strong> has secured clinical\u2011trial approvals across a wide allergic\u2011disease portfolio, reflecting its platform potential beyond the lead BLA indication:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Regulatory Status<\/th><th>Market<\/th><\/tr><\/thead><tbody><tr><td><strong>Seasonal Allergic Rhinitis<\/strong><\/td><td>BLA accepted by NMPA<\/td><td>China<\/td><\/tr><tr><td><strong>Chronic Spontaneous Urticaria<\/strong><\/td><td>Clinical trial approval<\/td><td>China<\/td><\/tr><tr><td><strong>Allergic Asthma<\/strong><\/td><td>Clinical trial approval<\/td><td>China<\/td><\/tr><tr><td><strong>Chronic Rhinosinusitis with Nasal Polyps<\/strong><\/td><td>Clinical trial approval<\/td><td>China<\/td><\/tr><tr><td><strong>Food Allergy<\/strong><\/td><td>Clinical trial approval<\/td><td>China<\/td><\/tr><tr><td><strong>Peanut Allergy<\/strong><\/td><td>IND approved<\/td><td>U.S. FDA<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Large Addressable Market:<\/strong> Seasonal allergic rhinitis affects a substantial patient population in China, and an effective anti\u2011IgE option with a novel sequence could capture meaningful share of a competitive allergy market<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> The breadth of clinical approvals \u2014 spanning urticaria, asthma, nasal polyps, and food allergy \u2014 positions <strong>LP\u2011003<\/strong> as a pipeline\u2011in\u2011a\u2011product for <strong>LongBio<\/strong>, with upside beyond the lead indication<\/li>\n\n\n\n<li><strong>International Footprint:<\/strong> U.S. FDA approval of the peanut\u2011allergy IND signals <strong>LongBio&#8217;s<\/strong> ambition to pursue global development, adding optionality and potential partnering interest<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> As an anti\u2011IgE candidate with a novel sequence, <strong>LP\u2011003<\/strong> will compete against established anti\u2011IgE biologics, where differentiation on efficacy, dosing, and safety will shape commercial uptake<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding LP\u2011003&#8217;s regulatory progress, clinical development, and commercial potential for LongBio Pharma. Actual results may differ due to risks including final approval timelines, clinical outcomes, competitive dynamics, and market adoption in allergic disease.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082100016_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026082100016_c.\"><\/object><a id=\"wp-block-file--media-58a029ad-cc3c-410e-91be-8de57d8e1944\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082100016_c.pdf\">2026082100016_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082100016_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-58a029ad-cc3c-410e-91be-8de57d8e1944\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LongBio Pharma (Suzhou) Co., Ltd. (HKG: 1779) announced that China&#8217;s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[65,4793,2483,38],"class_list":["post-75772","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-hkg-1779","tag-longbio-pharma","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>LongBio Pharma&#039;s LP\u2011003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti\u2011IgE Antibody Toward China Approval - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"LongBio Pharma (Suzhou) Co., Ltd. (HKG: 1779) announced that China&#039;s National Medical Products Administration (NMPA) has accepted its Biologics License Application (BLA) for LP\u2011003, an anti\u2011IgE antibody candidate, for the treatment of seasonal allergic rhinitis \u2014 marking a key regulatory step toward commercial approval.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75772\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LongBio Pharma&#039;s LP\u2011003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti\u2011IgE Antibody Toward China Approval\" \/>\n<meta property=\"og:description\" content=\"LongBio Pharma (Suzhou) Co., Ltd. (HKG: 1779) announced that China&#039;s National Medical Products Administration (NMPA) has accepted its Biologics License Application (BLA) for LP\u2011003, an anti\u2011IgE antibody candidate, for the treatment of seasonal allergic rhinitis \u2014 marking a key regulatory step toward commercial approval.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75772\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-21T04:19:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-21T04:19:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75772#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75772\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"LongBio Pharma&#8217;s LP\u2011003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti\u2011IgE Antibody Toward China Approval\",\"datePublished\":\"2026-08-21T04:19:36+00:00\",\"dateModified\":\"2026-08-21T04:19:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75772\"},\"wordCount\":416,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"HKG: 1779\",\"Longbio Pharma\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75772#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75772\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75772\",\"name\":\"LongBio Pharma's LP\u2011003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti\u2011IgE Antibody Toward China Approval - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-21T04:19:36+00:00\",\"dateModified\":\"2026-08-21T04:19:37+00:00\",\"description\":\"LongBio Pharma (Suzhou) Co., Ltd. (HKG: 1779) announced that China's National Medical Products Administration (NMPA) has accepted its Biologics License Application (BLA) for LP\u2011003, an anti\u2011IgE antibody candidate, for the treatment of seasonal allergic rhinitis \u2014 marking a key regulatory step toward commercial approval.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75772#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75772\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75772#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LongBio Pharma&#8217;s LP\u2011003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti\u2011IgE Antibody Toward China Approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"LongBio Pharma's LP\u2011003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti\u2011IgE Antibody Toward China Approval - Insight, China&#039;s Pharmaceutical Industry","description":"LongBio Pharma (Suzhou) Co., Ltd. (HKG: 1779) announced that China's National Medical Products Administration (NMPA) has accepted its Biologics License Application (BLA) for LP\u2011003, an anti\u2011IgE antibody candidate, for the treatment of seasonal allergic rhinitis \u2014 marking a key regulatory step toward commercial approval.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75772","og_locale":"en_US","og_type":"article","og_title":"LongBio Pharma's LP\u2011003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti\u2011IgE Antibody Toward China Approval","og_description":"LongBio Pharma (Suzhou) Co., Ltd. (HKG: 1779) announced that China's National Medical Products Administration (NMPA) has accepted its Biologics License Application (BLA) for LP\u2011003, an anti\u2011IgE antibody candidate, for the treatment of seasonal allergic rhinitis \u2014 marking a key regulatory step toward commercial approval.","og_url":"https:\/\/flcube.com\/?p=75772","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-21T04:19:36+00:00","article_modified_time":"2026-08-21T04:19:37+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75772#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75772"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"LongBio Pharma&#8217;s LP\u2011003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti\u2011IgE Antibody Toward China Approval","datePublished":"2026-08-21T04:19:36+00:00","dateModified":"2026-08-21T04:19:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75772"},"wordCount":416,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","HKG: 1779","Longbio Pharma","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75772#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75772","url":"https:\/\/flcube.com\/?p=75772","name":"LongBio Pharma's LP\u2011003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti\u2011IgE Antibody Toward China Approval - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-21T04:19:36+00:00","dateModified":"2026-08-21T04:19:37+00:00","description":"LongBio Pharma (Suzhou) Co., Ltd. (HKG: 1779) announced that China's National Medical Products Administration (NMPA) has accepted its Biologics License Application (BLA) for LP\u2011003, an anti\u2011IgE antibody candidate, for the treatment of seasonal allergic rhinitis \u2014 marking a key regulatory step toward commercial approval.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75772#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75772"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75772#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"LongBio Pharma&#8217;s LP\u2011003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti\u2011IgE Antibody Toward China Approval"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75772"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75772\/revisions"}],"predecessor-version":[{"id":75775,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75772\/revisions\/75775"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}